- Home
- HRZN vs DCTH Comparison
HRZN vs DCTH Comparison
Compare HRZN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- DCTH
- Stock Information
- Founded
- HRZN 2008
- DCTH 1988
- Country
- HRZN United States
- DCTH United States
- Employees
- HRZN N/A
- DCTH N/A
- Industry
- HRZN Finance/Investors Services
- DCTH Medical/Dental Instruments
- Sector
- HRZN Finance
- DCTH Health Care
- Exchange
- HRZN Nasdaq
- DCTH Nasdaq
- Market Cap
- HRZN 396.1M
- DCTH 352.0M
- IPO Year
- HRZN 2010
- DCTH N/A
- Fundamental
- Price
- HRZN $8.85
- DCTH $11.01
- Analyst Decision
- HRZN Sell
- DCTH Strong Buy
- Analyst Count
- HRZN 6
- DCTH 4
- Target Price
- HRZN $9.35
- DCTH $21.50
- AVG Volume (30 Days)
- HRZN 530.6K
- DCTH 378.5K
- Earning Date
- HRZN 10-29-2024
- DCTH 11-08-2024
- Dividend Yield
- HRZN 14.91%
- DCTH N/A
- EPS Growth
- HRZN N/A
- DCTH N/A
- EPS
- HRZN N/A
- DCTH N/A
- Revenue
- HRZN $104,553,000.00
- DCTH $22,644,000.00
- Revenue This Year
- HRZN N/A
- DCTH $1,605.13
- Revenue Next Year
- HRZN $7.48
- DCTH $111.67
- P/E Ratio
- HRZN N/A
- DCTH N/A
- Revenue Growth
- HRZN N/A
- DCTH 945.91
- 52 Week Low
- HRZN $8.46
- DCTH $3.70
- 52 Week High
- HRZN $13.73
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- HRZN 34.49
- DCTH 48.00
- Support Level
- HRZN $8.65
- DCTH $10.75
- Resistance Level
- HRZN $9.02
- DCTH $13.30
- Average True Range (ATR)
- HRZN 0.20
- DCTH 0.72
- MACD
- HRZN -0.03
- DCTH -0.13
- Stochastic Oscillator
- HRZN 39.39
- DCTH 10.19
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.